Major side effects occur after coronary syndrome

Published Date: 13 Mar 2023

OSA itself predicted the incidence of MACCE in non-obese patients.

Read Full News

Latest News

Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism

Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism

No New Safety Signals Over 3 Years in HS With Bimekizumab: Amit Garg, MD Amit Garg, MD

Amit Garg, MD, discusses 3-year pooled BE HEARD safety data on bimekizumab in moderate to severe hidradenitis suppurativa from EADV 2026.

Q&A: Early-Career Dermatology Pearls on Defensive Patients and HS Coding

Q&A: Early-Career Dermatology Pearls on Defensive Patients and HS Coding

RLS-1496 Cream Reduces Actinic Keratosis Lesions Mary Spellman, MD

Topical GPX4 inhibitor RLS-1496 1% reduced AK lesion counts by 43.5% vs 11.3% with untreated control at Day 57, with no application site reactions.

The HCPFive: Top News for Healthcare Providers from the Week of 10/18

The HCPFive: Top News for Healthcare Providers from the Week of 10/18

Lutikizumab Improves HS Pain, Flares in Phase 3 INTREPID Study

Lutikizumab Improves HS Pain, Flares in Phase 3 INTREPID Study

Todays Updates

QurAlis Reports ANQUR Interim Data for STATHMIN-2-Targeting Agent QRL-201 in ALS Marco Meglio

QurAlis reported interim ANQUR trial results showing target engagement, a biomarker signal, and a trend toward slower functional decline with QRL-201 in ALS.

Sevasemten Misses Primary Endpoint in Pivotal Trial for Becker Muscular Dystrophy Marco Meglio

Servier reported that sevasemten did not meet its primary or secondary endpoints in the pivotal GRAND CANYON trial for Becker muscular dystrophy.

GLP-1 RAs Linked to Lower Diabetes, CV Risk than Metformin in Prediabetes

GLP-1 RAs Linked to Lower Diabetes, CV Risk than Metformin in Prediabetes

Todays Updates

QurAlis Reports ANQUR Interim Data for STATHMIN-2-Targeting Agent QRL-201 in ALS Marco Meglio

QurAlis reported interim ANQUR trial results showing target engagement, a biomarker signal, and a trend toward slower functional decline with QRL-201 in ALS.

Sevasemten Misses Primary Endpoint in Pivotal Trial for Becker Muscular Dystrophy Marco Meglio

Servier reported that sevasemten did not meet its primary or secondary endpoints in the pivotal GRAND CANYON trial for Becker muscular dystrophy.

GLP-1 RAs Linked to Lower Diabetes, CV Risk than Metformin in Prediabetes

GLP-1 RAs Linked to Lower Diabetes, CV Risk than Metformin in Prediabetes

Latest News

Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism

Amit Garg, MD, discusses 3-year pooled BE HEARD safety data on bimekizumab in moderate to severe hidradenitis suppurativa from EADV 2026.

Q&A: Early-Career Dermatology Pearls on Defensive Patients and HS Coding

Topical GPX4 inhibitor RLS-1496 1% reduced AK lesion counts by 43.5% vs 11.3% with untreated control at Day 57, with no application site reactions.

The HCPFive: Top News for Healthcare Providers from the Week of 10/18

Lutikizumab Improves HS Pain, Flares in Phase 3 INTREPID Study

News All Time

EADV Congress 2026: 9 Late Breakers to Know

EADV Congress 2026: 9 Late Breakers to Know

Q&A: Gene Expression Testing, Ameluz PDT, and the Psoriasis Pipeline

Q&A: Gene Expression Testing, Ameluz PDT, and the Psoriasis Pipeline

Advances in Treating High-Impact Psoriasis from EADV 2026 Christopher G. Bunick, MD, PhD

Chris Bunick, MD, PhD, discusses 52-week UnlIMMited data showing risankizumab sustained clearance, itch relief, and quality-of-life gains.

EADV Congress 2026: 5 Atopic Dermatitis Headlines to Know

EADV Congress 2026: 5 Atopic Dermatitis Headlines to Know

Q&A: Insights on New Lebrikizumab Findings for Hand and Foot Atopic Dermatitis

Q&A: Insights on New Lebrikizumab Findings for Hand and Foot Atopic Dermatitis

Nemolizumab Safety, Real-World Use in AD, With Matthias Augustin, MD Matthias Augustin, MD

An ARCADIA investigator says patients in practice match the 3-year trial results and outlines next steps for IL-31 research.

No Signal for Birth Defects in Dupilumab Pregnancy Registry, With Tina Chambers, PhD, MPH Christina Chambers, PhD, MPH

Chambers discusses final results from a 7-year dupilumab pregnancy registry showing no evidence of increased risk for major birth defects or other outcomes.

Phase 3 Ritlecitinib Results in Vitiligo, With Iltefat Hamzavi, MD Iltefat Hamzavi, MD

Iltefat H. Hamzavi, MD, discusses phase 3 Tranquillo data showing higher facial and total body repigmentation with ritlecitinib in vitiligo.

Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD

Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD

Is Hidradenitis Suppurativa Underdiagnosed in Male Patients?

Is Hidradenitis Suppurativa Underdiagnosed in Male Patients?

Nemolizumab Sustains AD Response at 3 Years, With Matthias Augustin, MD Matthias Augustin, MD

Up to 91% of patients reached EASI-75 at week 152 in the ARCADIA LTE, with consistent safety and gains in itch and quality of life.

Denifanstat Sustains Acne Improvement Through 52 Weeks in Phase 3 Extension

Denifanstat Sustains Acne Improvement Through 52 Weeks in Phase 3 Extension

Upadacitinib Feasible for Palmoplantar Pustulosis: David Gleeson, BM BCH David Gleeson, BM BCH

Gleeson discusses JAKPPPOT data showing the therapy met all feasibility thresholds with a markedly larger response than historic placebo in PPP.

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Recommended News For You

All-Oral Treatment Combo for AML Earns FDA Nod

Video: Liver transplant for patients with advanced colorectal cancer

According to the CAPTIVATE Study, fixed-duration ibrutinib plus venetoclax may be beneficial for patients with high-risk chronic lymphocytic leukemia.

Where Did This Very Painful Gluteal Mass Come From?

ctDNA-Guided Adjuvant Therapy Cuts Bladder Cancer Costs

Screening tests that are non-invasive show promise in detecting colorectal cancer.

Unified Neuro/Psych Residency Program: New Proposal.

Recommended Articles For You

Nipple-Sparing Mastectomy: Oncologic Safety and Patient Selection Review 

Uncovering the Mystery of Burkitt's Lymphoma: A New Hope for Treatment 

Pediatric Cancer Organoid Models for Tumor Biology 

The Next Generation of Precision: How Multi-Specific Antibodies are Redefining Oncology's Future - A 2025 Review 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

BRAF Inhibition in Pediatric Ameloblastoma of the Jaw

2.

Two Survival Wins in NSCLC With Bispecific Seeking Worldwide Status

3.

Venetoclax Combo Shows Promise in Younger Patients With AML

4.

Men With Prostate Cancer Experience Less Hot Flashes When Using an Affordable Drug.

5.

Cancer care crowdfunding increasingly common, but rarely successful

1.

Altered Tumor–Host Tissue Mechanics During Progressive Cancer Growth

2.

Exploring New Treatment Options for Hemophilia: A Journey into the Unknown

3.

A Comprehensive Guide To Understanding Plasma Osmolality

4.

Unveiling the Chadwick Sign: A Revolutionary New Tool for Detecting Early Signs of Cancer

5.

Exploring the Normal Range of Monocytes: A Comprehensive Guide

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Understanding the Role of Multidisciplinary Cancer Care

2.

EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion

3.

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

4.

Efficient Management of First line ALK-rearranged NSCLC - Part VII

5.

The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot